

06/28/04 16:45 FAX 856 810 1454

LICATA & TYRRELL

001

**FACSIMILE COVER SHEET**

RECEIVED  
CENTRAL FAX CENTER

JUN 28 2004

**Licata & Tyrrell P.C.**

66 E. Main Street  
Marlton, New Jersey

Tel: (856) 810-1515  
Fax: (856) 810-1454

OFFICIAL

June 28, 2004

**TO: Examiner James Martinell (TC1600)**

**GROUP: 1645**

**FAX NUMBER: 703-872-9306**

**ATTORNEY DOCKET NO.: DEX-0279**

**SERIAL NO.: 10/001,885**

**FILED: November 20, 2001**

**NUMBER OF PAGES:**

**MESSAGE:** Attached please find Amendment Transmittal Letter, Reply to Restriction Requirement mailed May 28, 2004 and Certificate of Transmission by Facsimile.

**Kathleen A. Tyrrell, Registration No. 38,350**


**URGENT! PLEASE DELIVER IMMEDIATELY UPON RECEIPT. THANK YOU!**


\* \* \* \* \*

If you have any questions, or did not receive the proper number of pages, or had trouble during transmission, please call 856-810-1515.

**CONFIDENTIALITY NOTICE**

The information contained herein is confidential and is to be used only for the purpose of the trademark application. If you are not the trademark applicant, you are hereby notified that any disclosure, copying, distribution or taking of any action to enforce or any copies of the trademark application is strictly prohibited and will be held in violation of the trademark laws. If you have received this information in error, please immediately notify us by telephone in order to arrange for the return of the materials. Thank you.

<b>CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)</b>			Docket No.
Applicant(s): Salceda et al.			DEX-0279
Application No. 10/001,885	Filing Date November 20, 2001	Examiner James Martinell	Group Art Unit 1645
Invention: Compositions and Methods Relating to Ovary Specific Genes and Proteins			
<div style="text-align: right;">RECEIVED CENTRAL FAX CENTER JUN 28 2004</div>			
I hereby certify that this <u>Response to Restriction Requirement</u> (Identify type of correspondence)			
is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703-872-9306</u> )			
on <u>June 28, 2004</u> (Date)			
<div style="text-align: right;">OFFICIAL</div>			
<div style="text-align: right;">Kathleen A. Tyrrell (Typed or Printed Name of Person Signing Certificate)</div>			
<div style="text-align: right;"> (Signature)</div>			
Note: Each paper must have its own certificate of mailing.			

<b>AMENDMENT TRANSMITTAL LETTER (Large Entity)</b>				Docket No. <b>DEX-0279</b>	
Applicant(s): <b>Salceda et al.</b>					
Application No. <b>10/001,885</b>	Filing Date <b>November 20, 2001</b>	Examiner <b>James Martinell</b>	Customer No. <b>32800</b>	Group Art Unit <b>1645</b>	Confirmation No. <b>3414</b>
Invention: <b>Compositions and Methods Relating to Ovary Specific Genes and Proteins</b>					
<b>COMMISSIONER FOR PATENTS:</b>					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	19 -	20 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	2 -	3 =	0 x	\$86.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1619 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
 Signature Kathleen A. Tyrrell, Reg. No. 38,350			Dated: June 28, 2004		
Licata & Tyrrell P.C. 66 East Main Street Marlton, New Jersey 08053 Tel : 856-810-1515 Fax: 856-810-1454			I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.		
CC:			Signature of Person Mailing Correspondence		
			Typed or Printed Name of Person Mailing Correspondence		

F11LARGE/REV07

06/28/04 16:46 FAX 856 810 1454

LICATA & TYRRELL

RECEIVED  
CENTRAL FAX CENTER

0004

JUN 28 2004

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0279  
Inventors: Salceda et al.  
Serial No.: 10/001,843  
Filing Date: November 20, 2001  
Examiner: Martinell, James  
Group Art Unit: 1637  
Title: Compositions and Methods Relating to  
Ovary Specific Genes and Proteins

Certificate of Facsimile Transmission

I hereby certify that this document is being facsimile  
transmitted to the Patent and Trademark Office on  
the date shown below.

On June 28, 2004

  
Kathleen A. Tyrrell, Registration No. 38,350

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Reply to Restriction Requirement

This is a reply to the Restriction Requirement mailed May  
28, 2004 setting a one (1) month statutory period for response.  
Please enter the following remarks into the record.

Remarks begin at page 2.

Attorney Docket No.: DEX-0279  
Inventors: Salceda et al.  
Serial No.: 10/001,885  
Filing Date: November 20, 2001  
Page 2

#### REMARKS

Claims 1-17 are pending in the instant patent application.

Claims 1-17 have been subjected to a Restriction Requirement as follows:

Group I, claims 1-9, 14/1, and 15/1, drawn to nucleic acids, vectors, methods of making host cells, methods of making polypeptides and methods of diagnosis using nucleic acids, classified in class 536, subclass 23.5 and class 435, subclasses 252.3, 325, 6, 320.1, and 69.1;

Group II, claims 9 and 10 6, drawn to polypeptides, classified in class 530, subclass 350;

Group III, claims 12, 13, 14/6, and 15/6, drawn to antibodies, antibody assays and kits, classified in class 530, subclass 387.1 and class 435, subclass 7.1;

Group IV, claim 16, drawn to methods of treatment using antibodies, classified in class 424, subclass 130.1; and

Group V, claim 17, drawn to nucleic acid vaccines, classified in class 514, subclass 44.

The Examiner suggests that these Groups are distinct, each from the other.

Specifically, the Examiner suggests that the nucleic acids, vectors and host cells of Group I are materially different from the polypeptides of Group II and the antibodies of Group III and that the polypeptides of Group II are materially different from the antibodies of Group II and that both are materially different from the vaccines of Group V. Further, the Examiner suggests that the methods of Group I are not needed to make the polypeptides of Group II

Attorney Docket No.: DEX-0279  
Inventors: Salceda et al.  
Serial No.: 10/001,885  
Filing Date: November 20, 2001  
Page 3

or the antibodies of Group III nor to practice the method of Group IV and that the methods of Group IV are not needed to make the nucleic acid vaccines of Group V. Finally the Examiner suggests that the methods of Groups I, III and IV may be practiced independently.

Applicants respectfully traverse this Restriction Requirement.

MPEP §803 provides two criteria which must be met for a restriction requirement to be proper. The first is that the inventions be independent or distinct. The second is that there would be a serious burden on the Examiner if the restriction is not required. A search of prior art relating to an elected nucleic acid, polypeptide or antibody would also reveal any references teaching uses for the nucleic acid, polypeptide or antibody. Accordingly, Applicants believe that searching of all the claims, at least when limited to elected nucleic acids, polypeptides, or antibodies, is overlapping and would not place an undue burden on the Examiner if the Restriction is not made.

Thus, since this Restriction Requirement does not meet both criteria as set forth in MPEP § 803 to be proper, reconsideration and withdrawal of this Restriction Requirement is respectfully requested.


In addition, with respect to the election of a single sequence, MPEP § 803.04 clearly states that a reasonable number of nucleotide sequences, normally ten sequences, can be claimed in a single application. Accordingly, withdrawal of this sequence election requirement and reconsideration to include a more reasonable number of at

Attorney Docket No.: DEX-0279  
Inventors: Salceda et al.  
Serial No.: 10/001,885  
Filing Date: November 20, 2001  
Page 4

least 10 sequences in accordance with MPEP § 803.04 is also respectfully requested.

However, in an earnest effort to advance the prosecution of this case Applicants elect Group I, claims 1-9, 14/1 and 15/1 with traverse. Further, Applicants elect the nucleic acid of SEQ ID NO:31, encoding SEQ ID NO:125 with traverse.

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record.

Respectfully submitted,  
  
Kathleen A. Tyrrell  
Reg. No. 38,350

Date: June 28, 2004

LICATA & TYRRELL P.C.  
66 E. Main Street  
Marlton, New Jersey 08053  
(856) 810-1515